Get the Stockscreener App
12.74
5.99%
0.72
Pre-market:
12.73
-0.010
-0.08%
Xencor Inc stock is traded at $12.74, with a volume of 704.22K.
It is up +5.99% in the last 24 hours and up +10.49% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$12.02
Open:
$12.25
24h Volume:
704.22K
Relative Volume:
1.01
Market Cap:
$909.77M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-4.4083
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
+6.34%
1M Performance:
+10.49%
6M Performance:
+52.21%
1Y Performance:
-9.96%
1-Day Range:
$11.85
$12.80
1-Week Range:
$11.48
$14.54
52-Week Range:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.74 | 858.35M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor (NASDAQ:XNCR) VP Sells $31,689.70 in Stock - MarketBeat
Insider Selling: Xencor (NASDAQ:XNCR) SVP Sells 1,492 Shares of Stock - MarketBeat
Xencor SVP Eckert sells $17,747 in shares - Investing.com Nigeria
Xencor sr. VP Desjarlais sells $31,676 in stock - Investing.com
Dahiyat, Xencor CEO, sells $80k in XNCR stock - Investing.com
Xencor: Buy Rating Reaffirmed on Pipeline Momentum Despite Ultomiris Royalty Headwind - TipRanks
Xencor faces royalty dispute with Alexion over Ultomiris sales - Investing.com
Xencor Updates Outlook Amid Ultomiris Royalty Dispute - TipRanks
Xencor says Alexion disputes U.S. Ultomiris royalties; updates cash guidance to $380–400M - TradingView
Xencor faces $100M hit as Ultomiris US royalty checks stop - Stock Titan
XNCR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
(XNCR.O) | Stock Price & Latest News - Reuters
[144] Xencor Inc SEC Filing - Stock Titan
John Desjarlais plans to sell 2,663 XNCR shares (XNCR) — Form 144 notice - Stock Titan
Xencor at TD Cowen Conference: Strategic Focus on Oncology and Autoimmune By Investing.com - Investing.com South Africa
Xencor at TD Cowen Conference: Strategic Focus on Oncology and Autoimmune - Investing.com
Update Recap: Should value investors consider Xencor IncEarnings Recap Report & High Yield Equity Trading Tips - baoquankhu1.vn
Xencor, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
XNCR PE Ratio & Valuation, Is XNCR Overvalued - Intellectia AI
Xencor (NASDAQ:XNCR) Stock Rating Lowered by Wall Street Zen - MarketBeat
Xencor, Inc. (XNCR) Investor Outlook: Unpacking the 113% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Xencor, Inc. $XNCR Shares Purchased by Primecap Management Co. CA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Agilent (A), Xencor (XNCR) and Pennant Group (PNTG) - The Globe and Mail
Barclays Raises Xencor (XNCR) Price Target to $27, Maintains Ove - GuruFocus
Xencor (NASDAQ:XNCR) Shares Up 10.4% After Better-Than-Expected Earnings - MarketBeat
Xencor (NASDAQ:XNCR) Given New $27.00 Price Target at Barclays - MarketBeat
Xencor (XNCR) Losses Narrow On Trailing Basis Challenging Persistent Bearish Narratives - Sahm
Xencor Inc earnings beat by $0.51, revenue fell short of estimates - Investing.com Canada
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Xencor Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Xencor files for mixed shelf - marketscreener.com
Xencor (NASDAQ:XNCR) Issues Earnings Results - MarketBeat
Earnings Flash (XNCR) Xencor, Inc. Reports Q4 Revenue $28.2M, vs. FactSet Est of $30.0M - marketscreener.com
Xencor: Q4 Earnings Snapshot - marketscreener.com
Xencor Q4 revenue misses expectations, net loss narrows - TradingView
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
Xencor (XNCR) trims 2025 loss and outlines major trial plans - Stock Titan
Xencor recently updated its financial forecast, announcing that by the end of 2026, the company's cash reserves are expected to reach between $400 million and $430 million. - Bitget
Aug Catalysts: Is Xencor Inc a top pick in the sectorJuly 2025 Chart Watch & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Fed Impact: What hedge funds are buying Xencor Inc2025 Pullback Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Xencor to Participate at Upcoming Investor Conferences - Business Wire
Xencor Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
Xencor, Inc. (XNCR) Stock Analysis: Exploring A Biotech Giant With 145% Upside Potential - DirectorsTalk Interviews
What hedge funds are buying Xencor Inc.July 2025 Setups & Free High Return Stock Watch Alerts - mfd.ru
Will Xencor Inc. stock hit new highs in YEAREarnings Overview Report & Stepwise Swing Trade Plans - mfd.ru
Earnings Beat: Is Xencor Inc stock showing strong momentumDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Xencor (XNCR) to Release Quarterly Earnings on Thursday - MarketBeat
Big Money Moves: What is the Moat Score of Xencor Inc2025 Momentum Check & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug Swings: Can TACOU be recession proofTake Profit & Safe Capital Growth Stock Tips - baoquankhu1.vn
CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type - GlobeNewswire Inc.
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):